基于绩效的风险分担安排何时才有意义？ - Suppr

When do performance-based risk-sharing arrangements make sense?

作者信息

Drummond Michael

机构信息

Centre for Health Economics, Alcuin A Block, University of York, Heslington, York, YO10 5DD, UK,

出版信息

Eur J Health Econ. 2015 Jul;16(6):569-71. doi: 10.1007/s10198-015-0683-z.

DOI:10.1007/s10198-015-0683-z

PMID:25783211

Abstract

摘要

相似文献

When do performance-based risk-sharing arrangements make sense?

Eur J Health Econ. 2015 Jul;16(6):569-71. doi: 10.1007/s10198-015-0683-z.

Performance-based risk-sharing arrangements-good practices for design, implementation, and evaluation: report of the ISPOR good practices for performance-based risk-sharing arrangements task force.

Value Health. 2013 Jul-Aug;16(5):703-19. doi: 10.1016/j.jval.2013.04.011. Epub 2013 Jul 19.

Where are we on "risk-sharing" agreements?

Value Health. 2013 Jul-Aug;16(5):701-2. doi: 10.1016/j.jval.2013.04.012. Epub 2013 Jun 14.

USING CLAIMS DATA FOR EVIDENCE GENERATION IN MANAGED ENTRY AGREEMENTS.

Int J Technol Assess Health Care. 2016 Jan;32(1-2):69-77. doi: 10.1017/S0266462316000131. Epub 2016 Mar 15.

[Innovative agreements with the pharmaceutical industry: "pay for performance"].

Farm Hosp. 2010 Mar-Apr;34(2):53-5. doi: 10.1016/j.farma.2009.12.004. Epub 2010 Mar 6.

Emerging roles for pharmacists in performance-based risk-sharing arrangements.

Am J Health Syst Pharm. 2017 Jul 1;74(13):1007-1012. doi: 10.2146/ajhp160398. Epub 2017 May 18.

Private sector risk-sharing agreements in the United States: trends, barriers, and prospects.

Am J Manag Care. 2015 Sep;21(9):632-40.

Comment on: "Current status and trends in performance-based risk-sharing arrangements between healthcare payers and medical product manufacturers".

Appl Health Econ Health Policy. 2014 Oct;12(5):565. doi: 10.1007/s40258-014-0118-5.

Authors' reply to Curto and Garattini: "Current status and trends in performance-based risk-sharing arrangements between healthcare payers and medical product manufacturers".

Appl Health Econ Health Policy. 2014 Oct;12(5):567-8. doi: 10.1007/s40258-014-0119-4.

Performance-Based Risk-Sharing Arrangements: An Updated International Review.

Pharmacoeconomics. 2017 Oct;35(10):1063-1072. doi: 10.1007/s40273-017-0535-z.

引用本文的文献

Innovative Payment Mechanisms for High-Cost Medical Devices in Latin America: Experience in Designing Outcome Protection Programs in the Region.

J Mark Access Health Policy. 2025 Aug 4;13(3):39. doi: 10.3390/jmahp13030039. eCollection 2025 Sep.

Issues, Challenges and Opportunities for Economic Evaluations of Orphan Drugs in Rare Diseases: An Umbrella Review.

Pharmacoeconomics. 2024 Jun;42(6):619-631. doi: 10.1007/s40273-024-01370-2. Epub 2024 Apr 14.

Financial Outcomes of Managed Entry Agreements for Pharmaceuticals in Italy.

JAMA Health Forum. 2023 Dec 1;4(12):e234611. doi: 10.1001/jamahealthforum.2023.4611.

An evaluation of managed access agreements in England based on stakeholder experience.

Int J Technol Assess Health Care. 2023 Jul 27;39(1):e55. doi: 10.1017/S0266462323000478.

Coverage with evidence development for medical devices in Europe: Can practice meet theory?

Health Econ. 2022 Sep;31 Suppl 1(Suppl 1):179-194. doi: 10.1002/hec.4478. Epub 2022 Feb 26.

The economics of alternative payment models for pharmaceuticals.

Eur J Health Econ. 2021 Jun;22(4):559-569. doi: 10.1007/s10198-021-01274-4. Epub 2021 Mar 16.

Barriers and Opportunities for Implementation of Outcome-Based Spread Payments for High-Cost, One-Shot Curative Therapies.

Front Pharmacol. 2020 Dec 8;11:594446. doi: 10.3389/fphar.2020.594446. eCollection 2020.

Using Performance-Based Risk-Sharing Arrangements to Address Uncertainty in Indication-Based Pricing.

J Manag Care Spec Pharm. 2017 Oct;23(10):1010-1015. doi: 10.18553/jmcp.2017.23.10.1010.

Performance-Based Risk-Sharing Arrangements: An Updated International Review.

Pharmacoeconomics. 2017 Oct;35(10):1063-1072. doi: 10.1007/s40273-017-0535-z.

Incentivizing research into the effectiveness of medical devices.

Eur J Health Econ. 2016 Dec;17(9):1055-1058. doi: 10.1007/s10198-016-0820-3.

本文引用的文献

Validation of surrogate endpoints in advanced solid tumors: systematic review of statistical methods, results, and implications for policy makers.

Int J Technol Assess Health Care. 2014 Jul;30(3):312-24. doi: 10.1017/S0266462314000300.

Sharing risk between payer and provider by leasing health technologies: an affordable and effective reimbursement strategy for innovative technologies?

Value Health. 2014 Jun;17(4):438-44. doi: 10.1016/j.jval.2014.01.010. Epub 2014 Apr 29.

Performance-based risk-sharing arrangements-good practices for design, implementation, and evaluation: report of the ISPOR good practices for performance-based risk-sharing arrangements task force.

Value Health. 2013 Jul-Aug;16(5):703-19. doi: 10.1016/j.jval.2013.04.011. Epub 2013 Jul 19.

Where are we on "risk-sharing" agreements?

Value Health. 2013 Jul-Aug;16(5):701-2. doi: 10.1016/j.jval.2013.04.012. Epub 2013 Jun 14.

Risk sharing arrangements for pharmaceuticals: potential considerations and recommendations for European payers.

BMC Health Serv Res. 2010 Jun 7;10:153. doi: 10.1186/1472-6963-10-153.

Multiple sclerosis risk sharing scheme: a costly failure.

BMJ. 2010 Jun 3;340:c1672. doi: 10.1136/bmj.c1672.

Coverage with evidence development: an examination of conceptual and policy issues.

Int J Technol Assess Health Care. 2007 Fall;23(4):425-32. doi: 10.1017/S0266462307070651.

Establishing a comprehensive continuum from an evidentiary base to policy development for health technologies: the Ontario experience.

Int J Technol Assess Health Care. 2007 Summer;23(3):299-309. doi: 10.1017/s0266462307070456.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

When do performance-based risk-sharing arrangements make sense?

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献

本文引用的文献